<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4284">
  <stage>Registered</stage>
  <submitdate>16/01/2014</submitdate>
  <approvaldate>16/01/2014</approvaldate>
  <nctid>NCT02040480</nctid>
  <trial_identification>
    <studytitle>Bioavailability and Food Effect Study of Gelatin Formulation and Immediate Release Tablet Formulation of Afuresertib</studytitle>
    <scientifictitle>A Single Center, Randomized, Open-Label, Sequential, Single Dose, 3-Period Crossover Study to Evaluate the Bioavailability and Food Effect of a Gelatin Formulation and Immediate Release Tablet Formulation of Afuresertib, an AKT Inhibitor, in Normal Healthy Volunteers</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>201039</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Cancer</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - GSK2110183 Gelatin Capsule
Treatment: drugs - GSK2110183 IR Tablet

Experimental: Sequence 1 - Participants will receive treatment in following sequence in each of the three study periods (one treatment per period): ABC

Experimental: Sequence 2 - Participants will receive treatment in following sequence in each of the three study periods (one treatment per period): ACB

Experimental: Sequence 3 - Participants will receive treatment in following sequence in each of the three study periods (one treatment per period): BAC

Experimental: Sequence 4 - Participants will receive treatment in following sequence in each of the three study periods (one treatment per period): BCA

Experimental: Sequence 5 - Participants will receive treatment in following sequence in each of the three study periods (one treatment per period): CAB

Experimental: Sequence 6 - Participants will receive treatment in following sequence in each of the three study periods (one treatment per period): CBA


Treatment: drugs: GSK2110183 Gelatin Capsule
White opaque hard gelatin capsule with a unit dose strength of 25 milligrams (mg) for oral administration

Treatment: drugs: GSK2110183 IR Tablet
White round biconvex film coated IR tablet with a unit dose strength of 25 mg for oral administration

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Composite of pharmacokinetic (PK) parameters to determine relative bioavailability of afuresertib after administering it as a single dose in an original gelatin capsule in the fasted state and in a newly formulated IR tablet in the fed and fasted state. - PK parameters include: area under the plasma concentration-time curve from time zero to infinity (AUC [0-infinity]), area under the plasma concentration time curve from time zero to last time of quantifiable concentration (AUC [0-t]), maximum observed plasma concentration (Cmax), and time to Cmax (tmax).</outcome>
      <timepoint>PK Samples will be collected Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 120, and 168 hours post-dose</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Number of subjects with adverse events (AEs). - AEs will be collected from the start of Study Treatment and until the Follow-up contact.</outcome>
      <timepoint>Up to 9 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Clinical laboratory parameter assessment as a measure of safety and tolerability - Laboratory parameters include: hematology, clinical chemistry and urinalysis.</outcome>
      <timepoint>Up to 9 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Concomitant medications review as a measure of safety and tolerability</outcome>
      <timepoint>Up to 9 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Electrocardiogram (ECGs) measurement as a measure of safety and tolerability - Triplicate 12-lead ECGs will be collected at Screening; in each Dosing Period on Day 1 and Day 3 of Dosing Period; and at Follow-up.</outcome>
      <timepoint>Up to 9 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Vital sign measurement as a measure of safety and tolerability - Vital sign measurements will include systolic and diastolic blood pressure and pulse rate.</outcome>
      <timepoint>Up to 9 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Composite of PK parameter following single dose administration of IR tablet in fasted state - PK parameters include: AUC (0 - infinity), AUC (0 - t), Cmax, and tmax.</outcome>
      <timepoint>PK Samples will be collected Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 120, and 168 hours post-dose</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Provided signed written informed consent

          -  Healthy Male or female between 18 and 40 years of age inclusive, at the time the
             informed consent is obtained.

          -  Body weight &gt;=50 kilograms (kg) and body mass index (BMI) of &gt;=18 and &lt;= 32 kg/meter
             square (m^2).

          -  A female subject is eligible to participate if she is of (A) Non-childbearing
             potential defined as pre-menopausal females with a documented tubal ligation or
             hysterectomy or postmenopausal defined as 12 months of spontaneous amenorrhea (B)
             Child-bearing potential with negative pregnancy test as determined by serum human
             chorionic gonadotropin (hCG) test at Screening and prior to dosing, AND: agrees to use
             one of the acceptable contraception methods

          -  Male subjects with female partners of child-bearing potential must agree to use one of
             the contraception methods.

          -  Alanine aminotransferase, alkaline phosphatase and bilirubin &lt;=1.5xupper limit of
             normal (ULN) (isolated bilirubin &gt;1.5xULN is acceptable if bilirubin is fractionated
             and direct bilirubin &lt;35%).

          -  Based on single or averaged QT interval corrected (QTc) values of triplicate ECGs
             obtained over a brief recording period: QTcB &lt;450 millisecond (msec); or QTcB &lt;480
             msec in subjects with Bundle Branch Block.

          -  Able to swallow and retain orally administered study treatment and does not have any
             clinically significant gastrointestinal (GI) abnormalities that may alter absorption
             such as malabsorption syndrome or major resection of the stomach and/or bowels.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>40</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  Current or chronic history of liver disease, or known hepatic or biliary abnormalities
             (with the exception of Gilbert's syndrome or asymptomatic gallstones).

          -  History of gastroesophageal reflux disease, dyspepsia, peptic ulcer disease,
             gastrointestinal (GI) bleeding, GI surgery that could affect motility.

          -  History of atrial arrhythmias

          -  History of regular alcohol consumption within 6 months of the study defined as:

        An average weekly intake of &gt;21 units for males or &gt;14 units for females. One unit is
        equivalent to 10 grams (g) of alcohol: 270 mL of full strength beer (4.8%), 375 mL of mid
        strength beer (3.5%), 470 mL of light beer (2.7%), 250 mL pre-mix full strength spirit
        (5%), 100mL of wine (13.5%) and 30 mL of spirit (40%).

          -  History of sensitivity to any of the study medications, or components thereof or a
             history of drug or other allergy that, in the opinion of the Investigator or GSK
             Medical Monitor, contraindicates their participation

          -  A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody
             result within 3 months of Screening.

          -  Smoking or history or regular use of tobacco- or nicotine-containing products within 6
             months prior to screening.

          -  A positive drug/alcohol screen at Screening or upon check-in to the clinic on Day -1
             of each Dosing Period.

          -  A positive test for human immuno virus (HIV) antibody.

          -  Pregnant females as determined by positive serum hCG test at Screening or prior to
             dosing.

          -  Where participation in the study would result in donation of blood or blood products
             in excess of 500 mL within a 56 day period.

          -  Lactating females.

          -  The subject has participated in a clinical trial and has received an investigational
             product within the following time period prior to the first dosing day in the current
             study: 30 days, 5 half-lives or twice the duration of the biological effect of the
             investigational product (whichever is longer).

          -  Exposure to more than four new chemical entities within 12 months prior to the first
             dosing day.

          -  Any serious and/or unstable pre-existing medical, psychiatric disorder or other
             conditions that could interfere with subject's safety, obtaining informed consent or
             compliance to the study procedures.

          -  Any prohibited medications or recent consumption of citrus products.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/02/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>18</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/04/2014</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>GSK Investigational Site - Randwick</hospital>
    <postcode>2031 - Randwick</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>GlaxoSmithKline</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study is being conducted to measure the relative bioavailability of the original gelatin
      capsule formulation and a new formulation, immediate release (IR) tablet of Afuresertib
      (GSK2110183). The study will be composed of Screening, Treatment, and Follow-up Periods. A
      subject's total time involved in the study will be approximately 9 weeks. The study will
      enroll approximately 18 healthy volunteers.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02040480</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>GSK Clinical Trials</name>
      <address>GlaxoSmithKline</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>